Extending Clinical Equipoise to Phase 1 Trials Involving Patients: Unresolved Problems
Notwithstanding requirements for scientific/social value and risk/benefit proportionality in major research ethics policies, there are no widely accepted standards for these judgments in Phase 1 trials. This paper examines whether the principle of clinical equipoise can be used as a standard for ass...
Authors: | ; |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
Johns Hopkins Univ. Press
2010
|
In: |
Kennedy Institute of Ethics journal
Year: 2010, Volume: 20, Issue: 1, Pages: 75-98 |
Online Access: |
Presumably Free Access Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
Summary: | Notwithstanding requirements for scientific/social value and risk/benefit proportionality in major research ethics policies, there are no widely accepted standards for these judgments in Phase 1 trials. This paper examines whether the principle of clinical equipoise can be used as a standard for assessing the ratio of risk to direct-benefit presented by drugs administered in one category of Phase 1 study—first-in-human trials involving patients. On the basis of the supporting evidence for, and architecture of, Phase 1 studies, the articles offers two provisional conclusions: (1) the risks of drug administration in such trials cannot generally be justified on therapeutic grounds but by appeal to the social value of the research; and (2) a framework for adjudicating the ratio of risk/social-value must be developed. |
---|---|
ISSN: | 1086-3249 |
Contains: | Enthalten in: Kennedy Institute of Ethics, Kennedy Institute of Ethics journal
|
Persistent identifiers: | DOI: 10.1353/ken.0.0307 |